The effectiveness of best practise therapy after Botulinum Toxin A injections for adults diagnosed with neurological impairment and onset of spasticity.
The effectiveness of best practise therapy after Botulinum Toxin A injections for adults diagnosed with neurological impairment and onset of upper or lower limb spasticity as measured by attainment of goals.
Associate Professor Natasha Lannin
60 participants
Sep 7, 2010
Interventional
Conditions
Summary
This project will evaluate a client-centred motor-training intervention to improve functional outcome after botulinum toxin injection (BoNT-A) for people with a neurological injury (stroke or brain injury). Spasticity is common following stroke and those with greater spasticity typically experience less recovery. Current treatment for spasticity is to provide BoNT-A, an antispasticity drug. Some evidence exists to support the use of BoNT-A, but all studies recommend that BoNT-A be provided in conjunction with physical therapy. However, little direct evidence exists for optimum type, dosage and timing of therapy. Participants will be recruited on a consecutive admission basis from hospital outpatient spasticity clinic and receive an 8-week intervention which will include intensive one-on-one physiotherapy, behavioural strategies to increase patient motivation, and a task-specific home exercise program. A distinguishing feature of the program is that it is tailored to the specific needs of each participant, patients are extended to receive intensive physiotherapy practice, and the content is driven by the Clinical Guidelines for Stroke Management (National Stroke Foundation, 2010). Outcomes will be assessed at baseline, post-intervention, and at 3 months following the conclusion of intervention and will include assessment of functional movement, quality of life, and cost.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Group A: Best practice therapy. Best practise therapy provided by an occupational or physical therapist including evidence-based protocols for casting, electrical stimulation, task-specific movement training and home practise. 14 sessions (1 hour per session) of best practice therapy is provided over 8 weeks (2 weeks of casting (1 session per week), followed by 2 weeks of 3 x weekly therapy, then 2 weeks of 2x weekly therapy, and finishing with 2 weeks of 1 x weekly therapy). Group B: Best practise therapy plus botulinum toxin injections. A single dose of Botulinum toxin- A will be injected at baseline only and follow the 2009 British Society of Rehabilitation Medicine national guidelines (Spasticity in adults: management using botulinum toxin). Botox (Registered Trademark) botulinum toxin type A toxin is used in this trial. Botulinum toxin-A is injected intramuscularly into specifically selected muscles, determined by the treating rehabilitation physician. Larger superficial muscles may be identified with knowledge of surface anatomy; smaller muscles may require use of nerve stimulation or EMG to ensure correct placement of the injection, Dose will be individually determined based on the participant's identified needs and clinical goals. A maximum dose of 360U Botox (Registered Trademark) will be provided in a single adult injection session.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000091808